Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women (OWL-PCOS)
Primary Purpose
Polycystic Ovary Syndrome
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Orlistat/Meal Replacement/Lifestyle Modification
Loestrin 1/20
Combination of treatments
Sponsored by
About this trial
This is an interventional treatment trial for Polycystic Ovary Syndrome focused on measuring Polycystic Ovary Syndrome
Eligibility Criteria
Couples Inclusion Criteria:
- Partner with sperm concentration of >=14 million/mL in at least one ejaculate with motile sperm.
- Ability to have regular intercourse 2-3 times per week during the ovulation induction phase of study.
- At least one patent tube and normal uterine cavity as determined by sonohysterogram, hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years, or confirmation of a intrauterine pregnancy within the past 2 years.
- No previous sterilization procedures(vasectomy, tubal ligation) that have been reversed.
- Wanting to seek pregnancy.
Inclusion Criteria:
- Chronic anovulation or oligomenorrhea defined as intermenstrual periods of >= 45 days or a total of <=8 periods per year.
- Hyperandrogenism will be an elevated total testosterone >=50 ng/dL.
- Hirsutism determined by a modified Ferriman-Gallwey Score >8.
- PCO on ultrasound (12 or more follicles measuring 2-9 mm in diameter).
- BMI >=27 to <=42.
- Normal EKG to rule out any abnormalities with the heart.
Exclusion Criteria:
- Current pregnancy.
- Patients on oral contraceptives, depo progestins, or hormonal implants.
- Patients with hyperprolactinemia defined as two prolactin levels at least one week apart >30 ng/mL.
- Patients with known 21-hydroxylase deficiency by a fasting 17-hydroxyprogesterone (17-OHP) level <2 ng/mL and ACTH stimulation test as needed, or other enzyme deficiency.
- Patients with menopausal FSH levels >20 mIU/mL.
- Patients with uncorrected thyroid disease (TSH <0.45 mIU/ML or >4.5 mIU/ML).
- Patients diagnosed with Type1 or Type II diabetes.
- Patients with liver disease defined as AST or ALT >2 times normal or total bilirubin >2.5 mg/dL.
- Patients with renal disease defined as BUN >30 mg/dL or serum creatinine >1.4 mg/dL.
- Patients with significant anemia (Hemoglobin <10 mg/dL).
- Patients with a history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.
- Patients with known heart disease that is likely to be exacerbated by pregnancy.
- Patients with a history of , or suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma. A normal PAP smear or reassuring colposcopy based on current ACOG guidelines will be required.
- Patient with current history of alcohol abuse.
- Patients enrolled simultaneously into other investigative studies.
- Patients taking other medications know to affect reproductive function or metabolism.
- Patients with a suspected adrenal or ovarian tumor secreting androgens.
- Patients with suspected Cushing's syndrome.
- Patients who have undergone a bariatric surgery procedure in the recent past (<12 months).
- Patients with untreated poorly controlled hypertension defined as systolic blood pressure >=150 mm Hg or average diastolic >=100 mm Hg on three measurements obtained 5 minutes apart. If treated, average systolic blood pressure >= 140 mm Hg or average diastolic >= 90 mm Hg.
- Patients with medical conditions that represent contraindications to orlistat, OCP, clomiphene, and/or pregnancy.
- Patients currently participating in lifestyle intervention program (Weight Watchers, Atkins Diet, Curves) or lost more than 5% body weight within the last 6 months.
Sites / Locations
- Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
- University of Pennsylvania, Department of Obstetrics and Gynecology
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
Lifestyle intervention
Oral Contraceptives (OCP)
Lifestyle/OCP Combined
Arm Description
Orlistat/Meal Replacement/Lifestyle Modification
Loestrin 1/20
Combination of treatments
Outcomes
Primary Outcome Measures
Live Birth Rate
Secondary Outcome Measures
Ovulation Rate
Change in Weight
Change from baseline to end of the 4-month intervention.
Prevalence of Metabolic Syndrome
Full Information
NCT ID
NCT00704912
First Posted
June 23, 2008
Last Updated
November 3, 2016
Sponsor
Milton S. Hershey Medical Center
Collaborators
University of Pennsylvania
1. Study Identification
Unique Protocol Identification Number
NCT00704912
Brief Title
Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women
Acronym
OWL-PCOS
Official Title
Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
September 2008 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
March 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Milton S. Hershey Medical Center
Collaborators
University of Pennsylvania
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The goal of this three-armed randomized controlled trial is to establish the relative roles of treatment of hyperandrogenism versus obesity (as the largest modifiable factor contributing to insulin resistance) in treating infertility and improving pregnancy outcomes among obese PCOS women. The investigators hypothesize that the key to restoring ovulation leading to live birth is to correct hyperandrogenism with oral contraceptive pills, but the key to avoiding later pregnancy complications is to improve insulin sensitivity with weight loss.
Detailed Description
Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility among women, and women with PCOS are at increased risk for pregnancy complications such as gestational diabetes and pre-eclampsia. Both hyperandrogenism (HA) and obesity exacerbated insulin resistance (IR) are characteristics of the syndrome, and are targets for treatment, but which should be the predominant focus is still unknown. Phase 1 of this study will be a randomized trial of three preconception interventions in infertile women with PCOS. The first arm will be a combined intervention of medication, meal replacements, and lifestyle modification to improve IR. Orlistat is a gastric lipase inhibitor that reduces the absorption of fat contained in a meal by about 30%. The second arm will be the use of a continuous OCP for 4 months to improve HA. Lo-Estrin 1/20 will be used in a continuous method for 4 months to suppress the ovary. The third arm is the combination of both to improve HA an IR. Phase II of this study will involve ovulation induction with clomiphene citrate with hopeful outcome of pregnancy. Finally, Phase III involve following the pregnancies for outcomes and complications.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Polycystic Ovary Syndrome
Keywords
Polycystic Ovary Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
217 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Lifestyle intervention
Arm Type
Active Comparator
Arm Description
Orlistat/Meal Replacement/Lifestyle Modification
Arm Title
Oral Contraceptives (OCP)
Arm Type
Active Comparator
Arm Description
Loestrin 1/20
Arm Title
Lifestyle/OCP Combined
Arm Type
Active Comparator
Arm Description
Combination of treatments
Intervention Type
Drug
Intervention Name(s)
Orlistat/Meal Replacement/Lifestyle Modification
Other Intervention Name(s)
Orlistat, Alli, Lifestyle Intervention, Weight Loss
Intervention Description
Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.
Intervention Type
Drug
Intervention Name(s)
Loestrin 1/20
Other Intervention Name(s)
OCP, Oral Contraceptive
Intervention Description
Patients will be started on a low dose containing OCP for a continuous 4 month period.
Intervention Type
Drug
Intervention Name(s)
Combination of treatments
Other Intervention Name(s)
Orlistat, Alli, OCP, Oral Contraceptive, Weight Loss, Lifestyle Intervention
Intervention Description
Medications will be administered as described for the other 2 arms.
Primary Outcome Measure Information:
Title
Live Birth Rate
Time Frame
Participants were followed for 4 months of attempted conception and those who conceived were then followed for the duration of their pregnancy, approximately 9 months.
Secondary Outcome Measure Information:
Title
Ovulation Rate
Time Frame
Up to 4 months
Title
Change in Weight
Description
Change from baseline to end of the 4-month intervention.
Time Frame
Baseline, 4 months
Title
Prevalence of Metabolic Syndrome
Time Frame
Baseline, 4 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Couples Inclusion Criteria:
Partner with sperm concentration of >=14 million/mL in at least one ejaculate with motile sperm.
Ability to have regular intercourse 2-3 times per week during the ovulation induction phase of study.
At least one patent tube and normal uterine cavity as determined by sonohysterogram, hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years, or confirmation of a intrauterine pregnancy within the past 2 years.
No previous sterilization procedures(vasectomy, tubal ligation) that have been reversed.
Wanting to seek pregnancy.
Inclusion Criteria:
Chronic anovulation or oligomenorrhea defined as intermenstrual periods of >= 45 days or a total of <=8 periods per year.
Hyperandrogenism will be an elevated total testosterone >=50 ng/dL.
Hirsutism determined by a modified Ferriman-Gallwey Score >8.
PCO on ultrasound (12 or more follicles measuring 2-9 mm in diameter).
BMI >=27 to <=42.
Normal EKG to rule out any abnormalities with the heart.
Exclusion Criteria:
Current pregnancy.
Patients on oral contraceptives, depo progestins, or hormonal implants.
Patients with hyperprolactinemia defined as two prolactin levels at least one week apart >30 ng/mL.
Patients with known 21-hydroxylase deficiency by a fasting 17-hydroxyprogesterone (17-OHP) level <2 ng/mL and ACTH stimulation test as needed, or other enzyme deficiency.
Patients with menopausal FSH levels >20 mIU/mL.
Patients with uncorrected thyroid disease (TSH <0.45 mIU/ML or >4.5 mIU/ML).
Patients diagnosed with Type1 or Type II diabetes.
Patients with liver disease defined as AST or ALT >2 times normal or total bilirubin >2.5 mg/dL.
Patients with renal disease defined as BUN >30 mg/dL or serum creatinine >1.4 mg/dL.
Patients with significant anemia (Hemoglobin <10 mg/dL).
Patients with a history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.
Patients with known heart disease that is likely to be exacerbated by pregnancy.
Patients with a history of , or suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma. A normal PAP smear or reassuring colposcopy based on current ACOG guidelines will be required.
Patient with current history of alcohol abuse.
Patients enrolled simultaneously into other investigative studies.
Patients taking other medications know to affect reproductive function or metabolism.
Patients with a suspected adrenal or ovarian tumor secreting androgens.
Patients with suspected Cushing's syndrome.
Patients who have undergone a bariatric surgery procedure in the recent past (<12 months).
Patients with untreated poorly controlled hypertension defined as systolic blood pressure >=150 mm Hg or average diastolic >=100 mm Hg on three measurements obtained 5 minutes apart. If treated, average systolic blood pressure >= 140 mm Hg or average diastolic >= 90 mm Hg.
Patients with medical conditions that represent contraindications to orlistat, OCP, clomiphene, and/or pregnancy.
Patients currently participating in lifestyle intervention program (Weight Watchers, Atkins Diet, Curves) or lost more than 5% body weight within the last 6 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard S Legro, M.D.
Organizational Affiliation
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christos Coutifaris, M.D., Ph.D.
Organizational Affiliation
Universtiy of Pennsylvania, Department of Obstetrics and Gynecology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Facility Name
University of Pennsylvania, Department of Obstetrics and Gynecology
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
33059886
Citation
Steinberg Weiss M, Roe AH, Allison KC, Dodson WC, Kris-Etherton PM, Kunselman AR, Stetter CM, Williams NI, Gnatuk CL, Estes SJ, Sarwer DB, Coutifaris C, Legro RS, Dokras A. Lifestyle modifications alone or combined with hormonal contraceptives improve sexual dysfunction in women with polycystic ovary syndrome. Fertil Steril. 2021 Feb;115(2):474-482. doi: 10.1016/j.fertnstert.2020.08.1396. Epub 2020 Oct 12.
Results Reference
derived
PubMed Identifier
32968804
Citation
Shah A, Dodson WC, Kris-Etherton PM, Kunselman AR, Stetter CM, Gnatuk CL, Estes SJ, Allison KC, Sarwer DB, Sluss PM, Coutifaris C, Dokras A, Legro RS. Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ss Superfamily Hormones in PCOS. J Clin Endocrinol Metab. 2021 Jan 1;106(1):108-119. doi: 10.1210/clinem/dgaa682.
Results Reference
derived
PubMed Identifier
27253669
Citation
Dokras A, Sarwer DB, Allison KC, Milman L, Kris-Etherton PM, Kunselman AR, Stetter CM, Williams NI, Gnatuk CL, Estes SJ, Fleming J, Coutifaris C, Legro RS. Weight Loss and Lowering Androgens Predict Improvements in Health-Related Quality of Life in Women With PCOS. J Clin Endocrinol Metab. 2016 Aug;101(8):2966-74. doi: 10.1210/jc.2016-1896. Epub 2016 Jun 2.
Results Reference
derived
PubMed Identifier
27172435
Citation
Legro RS, Dodson WC, Kunselman AR, Stetter CM, Kris-Etherton PM, Williams NI, Gnatuk CL, Estes SJ, Allison KC, Sarwer DB, Diamond MP, Schlaff WD, Casson PR, Christman GM, Barnhart KT, Bates GW, Usadi R, Lucidi S, Baker V, Zhang H, Eisenberg E, Coutifaris C, Dokras A. Benefit of Delayed Fertility Therapy With Preconception Weight Loss Over Immediate Therapy in Obese Women With PCOS. J Clin Endocrinol Metab. 2016 Jul;101(7):2658-66. doi: 10.1210/jc.2016-1659. Epub 2016 May 12.
Results Reference
derived
PubMed Identifier
26401593
Citation
Legro RS, Dodson WC, Kris-Etherton PM, Kunselman AR, Stetter CM, Williams NI, Gnatuk CL, Estes SJ, Fleming J, Allison KC, Sarwer DB, Coutifaris C, Dokras A. Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2015 Nov;100(11):4048-58. doi: 10.1210/jc.2015-2778. Epub 2015 Sep 24.
Results Reference
derived
Links:
URL
http://www.hmc.psu.edu
Description
Click here for more information about this study.
Learn more about this trial
Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women
We'll reach out to this number within 24 hrs